Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
3.840
-0.150 (-3.76%)
At close: Nov 16, 2026, 4:00 PM EST
3.925
+0.085 (2.20%)
After-hours: Nov 16, 2026, 7:59 PM EST
Nuvation Bio Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Nuvation Bio stock has a consensus rating of "Strong Buy" and an average price target of $12.45. The average 1-year stock price forecast is 224.22% higher than the current stock price, while the lowest is $7.00 (+82.29%) and the highest is $21 (+446.88%).
Price Target: $12.45 (+224.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Nuvation Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 9 | 9 | 9 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JonesTrading | JonesTrading | Buy Maintains $12 | Buy | Maintains | $12 | +212.50% | Nov 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $13 → $11 | Buy | Reiterates | $13 → $11 | +186.46% | Nov 9, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 | Buy | Maintains | $11 | +186.46% | Nov 6, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $14 → $13 | Buy | Maintains | $14 → $13 | +238.54% | Nov 5, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $20 → $17 | Buy | Reiterates | $20 → $17 | +342.71% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
203.17M
from 62.90M
Increased by 222.99%
Revenue Next Year
250.89M
from 203.17M
Increased by 23.49%
EPS This Year
-0.29
from -0.49
EPS Next Year
-0.08
from -0.29
EPS and Forward PE are based on non-GAAP adjusted numbers.